- Home
- SJW vs GLPG Comparison
SJW vs GLPG Comparison
Compare SJW & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJW
- GLPG
- Stock Information
- Founded
- SJW 1866
- GLPG 1999
- Country
- SJW United States
- GLPG Belgium
- Employees
- SJW N/A
- GLPG N/A
- Industry
- SJW Water Supply
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- SJW Utilities
- GLPG Health Care
- Exchange
- SJW Nasdaq
- GLPG Nasdaq
- Market Cap
- SJW 1.8B
- GLPG 1.8B
- IPO Year
- SJW N/A
- GLPG 2005
- Fundamental
- Price
- SJW $55.07
- GLPG $24.11
- Analyst Decision
- SJW Buy
- GLPG Sell
- Analyst Count
- SJW 2
- GLPG 4
- Target Price
- SJW $56.00
- GLPG $25.33
- AVG Volume (30 Days)
- SJW 233.8K
- GLPG 149.1K
- Earning Date
- SJW 04-24-2025
- GLPG 04-23-2025
- Dividend Yield
- SJW 3.12%
- GLPG N/A
- EPS Growth
- SJW 7.09
- GLPG N/A
- EPS
- SJW 2.87
- GLPG 1.16
- Revenue
- SJW $748,439,000.00
- GLPG $285,380,474.00
- Revenue This Year
- SJW $3.60
- GLPG $0.08
- Revenue Next Year
- SJW $1.50
- GLPG $0.23
- P/E Ratio
- SJW $18.77
- GLPG $21.58
- Revenue Growth
- SJW 11.65
- GLPG 14.99
- 52 Week Low
- SJW $44.91
- GLPG $22.36
- 52 Week High
- SJW $62.18
- GLPG $32.17
- Technical
- Relative Strength Index (RSI)
- SJW 59.22
- GLPG 36.16
- Support Level
- SJW $53.40
- GLPG $24.39
- Resistance Level
- SJW $55.82
- GLPG $25.72
- Average True Range (ATR)
- SJW 1.25
- GLPG 0.50
- MACD
- SJW 0.15
- GLPG -0.18
- Stochastic Oscillator
- SJW 78.98
- GLPG 4.75
Stock Price Comparison Chart: SJW vs GLPG
About SJW SJW Group (DE)
SJW Group is a U.S. water utility services holding company that provides, stores, purifies and distributes water. The company predominantly operates in various Californian municipalities and also has operations in other states. Its operating segments include Water Utility Services and Real Estate Services. The majority of the company's revenue is derived from its water utility services segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.